Another win for biosimilar arthritis drugs
In another win for biosimilar drugs, FDA staff recently decided that Celltrion and Pfizer’s biosimilar (Remsima) to Johnson & Johnson’s Remicade for rheumatoid arthritis was “highly similar” to...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Biosimilar offers hope of lower-cost treatment of autoimmune diseases
While an FDA panel recently decided that Celltrion's biosimilar, Remsima (infliximab), is “highly similar” to the branded monoclonal antibody, Remicade (infliximab), in its effect on a variety of...
View Article
More Pages to Explore .....
